- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Biceps Brachii Muscle.
Displaying page 1 of 1.
EudraCT Number: 2017-003117-25 | Sponsor Protocol Number: V3.0 | Start Date*: 2018-05-17 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Longitudinal chemodenervation effects of botulinum toxin A after intramuscular application and the impact of physical activity | ||
Medical condition: Spastic hemiparesis with involvement of the M. biceps brachii | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004089-13 | Sponsor Protocol Number: KLF/K/019811 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Cassella-med GmbH & Co. KG | |||||||||||||
Full Title: Placebo-controlled exploratory pilot study to investigate the effect and onset of action of Traumaplant® for delayed onset muscle soreness. | |||||||||||||
Medical condition: delayed onset muscle soreness (DOMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003359-33 | Sponsor Protocol Number: MABS06 | Start Date*: 2023-06-21 | |||||||||||
Sponsor Name:MUMC | |||||||||||||
Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers | |||||||||||||
Medical condition: Mitochondrial myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004608-32 | Sponsor Protocol Number: DYN101-C102 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dynacure | |||||||||||||
Full Title: A Phase 1/2, multicenter, open-label, dose-confirmation trial to evaluate the safety and preliminary efficacy of DYN101 in subjects 2 to 17 years of age with centronuclear myopathy caused by mutati... | |||||||||||||
Medical condition: Centronuclear myopathy (CNM), in subjects 2 to 17 years of age (all ages inclusive)caused by mutations in the myotubularin1 (MTM1) or dynamin 2 (DNM2) gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002069-52 | Sponsor Protocol Number: 4045-301 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) SE (Completed) DE (Completed) FR (Ongoing) ES (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing) BG (Ongoing) PL (Ongoing) IE (Ongoing) DK (Ongoing) GR (Ongoing) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002921-31 | Sponsor Protocol Number: C3391003 | Start Date*: 2020-09-29 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | |||||||||||||
Medical condition: DUCHENNE MUSCULAR DYSTROPHY (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Temporarily Halted) FR (Ongoing) BE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000321-80 | Sponsor Protocol Number: FGCL-3019-079 | Start Date*: 2023-05-16 |
Sponsor Name:FibroGen, Inc. | ||
Full Title: Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy | ||
Medical condition: Duchenne Muscular Dystrophy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-000305-79 | Sponsor Protocol Number: A083-04 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:Acceleron Pharma Inc. | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients with C... | |||||||||||||
Medical condition: Facioscapulohumeral Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006255-34 | Sponsor Protocol Number: BN43703 | Start Date*: 2022-08-26 |
Sponsor Name:F.Hoffmann-La Roche Ltd | ||
Full Title: A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE PHARMACODYNAMICS, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7204239 IN PARTICIPANTS WITH ... | ||
Medical condition: Facioscapulohumeral muscular dystrophy (FSHD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Trial now transitioned) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000698-26 | Sponsor Protocol Number: FGCL-3019-093 | Start Date*: 2023-01-17 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Subjects with Non-ambulatory Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Non-ambulatory Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005375-16 | Sponsor Protocol Number: A-99-52120-162 | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Institut Produits Synthèse (IPSEN) AB | |||||||||||||
Full Title: A PHASE III PROSPECTIVE, MULTI-CENTER, RANDOMISED, EVALUATOR-BLINDED STUDY TO COMPARE NEUROMUSCULAR JUNCTION (NMJ) TARGETED TECHNIQUE FOR DYSPORT INJECTIONS IN UPPER LIMB SPASTICITY POST STROKE OR ... | |||||||||||||
Medical condition: Upper limb spasticity post stroke or traumatic brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.